PTEN and meningioma: Recently, in a multi-omics study, Nassiri et al. identified a highly aggressive subgroup of meningioma, referred as the MG4 proliferative group, characterized by a high fraction of disrupted genome, frequent PTEN loss, high MCM expression, poor clinical outcome, and sensitivity to vorinostat, a histone deacetylase inhibitor [28].